Fig. 3: p38-MK2 signaling is required for ischemia-induced cell death.

A LN229 cells were cultured under the ischemic condition for the indicated time and subjected to western blotting. B LN229^vector, LN229^KRAS(G12D), or LN229^{PIK3CA(H1047R)} cells cultured under regular or ischemic conditions were subjected to western blotting. C LN229 cells treated by indicated p38 inhibitors or the DMSO control were subjected to western blotting. D Viability of LN229^KRAS(G12D) and LN229^{PIK3CA(H1047R)} cells treated with indicated p38 inhibitors (AMG548, 2 μM; VX745, 2 μM; Scio469, 1 μM) under ischemic conditions. Ordinary one-way ANOVA test. E LN229^KRAS(G12D) or LN229^{PIK3CA(H1047R)} cells stably transduced by indicated shRNAs targeting p38α or a scrambled shRNA control were subjected to western blotting. F Cells, as indicated in E, were cultured in the ischemic condition for 18 h and subjected to crystal violet cell viability assay. Ordinary one-way ANOVA test. G Viability of LN229^KRAS(G12D) and LN229^{PIK3CA(H1047R)} cells treated with DMSO or MK25 (10 μM) under ischemic conditions. Student’s t test. H LN229^KRAS(G12D) or LN229^{PIK3CA(H1047R)} cells stably transduced by indicated shRNAs targeting MK2 or a scrambled shRNA control were subjected to western blotting. I Cells, as indicated in H, were cultured in the ischemic condition for 18 h and subjected to crystal violet cell viability assay. Ordinary one-way ANOVA test.